[en] A series of medical disciplines benefit from the emergence of diverse targeted therapies using monoclonal antibodies. Skin is affected by adverse events of such therapies primarily targeting internal cancers. As a unique event in medicine, some of the skin adverse effects are predictive markers of the therapeutic antineoplastic activity. This fact concerns the paroxismal acneiform eruption and the inflammatory flare-up of actinic keratoses. Such a situation is linked to the fact that these specific "unwanted" effects are not really side effects but rather represent the direct pharmacological consequence of the activity directed to the EGF receptors which are particularly abundant in the follicular ostium and in precursor lesions to skin carcinomas.
Disciplines :
Dermatology
Author, co-author :
Quatresooz, Pascale ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie
Rorive, Andrée ; Centre Hospitalier Universitaire de Liège - CHU > Oncologie médicale
Paquet, Philippe ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie
Pierard, Claudine ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie
Pierard, Gérald ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie
Language :
French
Title :
Le paradoxe des effets cutanes indesirables, mais predictifs de l'efficacite des therapies ciblees anticancereuses.
Alternative titles :
[en] Cutaneous adverse effects predicting the efficacy of targeted antineoplastic therapies
Segaert S, Van Cutsem E.- Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol, 2005, 16, 1425-1433. (Pubitemid 41222414)
Piérard-Franchimont C, Blaise G, Paquet P, et al.- Acné iatrogène paroxystique et les inhibiteurs du récepteur du facteur de croissance épidermique (EGFR). Rev Med Liège, 2007, 62, 11-14.
Wyatt JA, Leonard GD, Sachs DL.- Cutaneous reactions to chemotherapy and their management. Am J Clin Dermatol, 2006, 7, 45-63. (Pubitemid 43295808)
Piérard GE, Paquet P, Piérard-Franchimont C, et al.- Réactions cutanées indésirables à la chimiothérapie et leurs traitements. Rev Med Liège, 2007, 62, 457-462.
Piérard-Franchimont C, Colige A, Arrese Estrada J, et al.- Immuno-histochemical expression of epidermal growth factor receptors in nuclei of a subpopulation of keratinocytes and sweat gland cells. Dermatologica, 1991, 183, 7-9.
Grünwald V, Hidalgo M.- Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst, 2003, 95, 851-867. (Pubitemid 36833877)
Dalle S, Thieblemont C, Thomas L, Dumontet C.- Monoclonal antibodies in clinical oncology. Anticancer Agents Med Chem, 2008, 8, 523-532.
Oldham RK, Dillman RO.- Monoclonal antibodies in cancer therapy : 25 years of progress. J Clin Oncol, 2008, 26, 1774-1777.
Robert C, Soria JC, Spatz A, et al.- Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol, 2005, 6, 491-500. (Pubitemid 40903630)
Segaert S, Tabernero J, Chosidow O, et al.- The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J Dtsch Dermatol Ges, 2005, 3, 599-606. (Pubitemid 41647826)
Morse L, Calarese P.- EGFR-targeted therapy and related skin toxicity. Semin Oncol Nurs, 2006, 22, 152-162. (Pubitemid 44163102)
Lacouture ME, Melosky BL.- Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor : a dermatology-oncology perspective. Skin Therapy Lett, 2007, 12, 1-5.
Bernier J, Bonner J, Vermorken JB, et al.- Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol, 2008, 19, 142-149.
Kimyai-Asadi A, Ming H.- Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors : a case report. Arch Dermatol, 2002, 138, 129-130. (Pubitemid 34056253)
Molinari E, De Quatrebarbes J, André T, Aractingi S.- Cetuximab induced acne. Dermatology, 2005, 211, 330-333.
Adams DH, Nutt T.- A case report and discussion of cetuximab-induced folliculitis. Am J Clin Dermatol, 2006, 7, 333-336. (Pubitemid 46998584)
Agero AL, Dusza SW, Benvenuto-Andrade C, et al.- Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol, 2006, 55, 657-670. (Pubitemid 44436627)
Tejpar S, Peeters M, Humblet Y, et al.- Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer with no or slight skin reactions on cetuximab standard dose treatment (Everest) : pharmaco-kinetic, pharmacodynamic and efficacy data. Proc Am Soc Clin Oncol, 2007, 25, 4037.
Roe E, Garcia Muret MP, Marcuello E, et al.- Description and management of cutaneous side effects during cetuximab or erlotinib treatments : a prospective study of 30 patients. J Am Acad Dermatol, 2006, 55, 429-437. (Pubitemid 44189595)
Budach W, Bölke E, Homey B.- Severe cutaneous reaction during radiation therapy with concurrent cetuximab. N Engl J Med, 2007, 357, 514-515. (Pubitemid 47204904)
Berger B, Belka C.- Severe skin reaction secondary to concomitant radiotherapy plus cetuximab. Radiat Oncol, 2008, 3, 5.
Cowen EW.- Epidermal growth factor receptor inhibitors : a new era of drug reactions in a new era of cancer therapy. J Am Acad Dermatol, 2007, 56, 514-517. (Pubitemid 46273855)
Lunch TJ, Kim ES, Eaby B, et al.- Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist, 2007, 12, 610-621. (Pubitemid 350012125)
Gutzmer R, Werfel T, Mao R, et al.- Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy. Br J Dermatol, 2005, 153, 849-851. (Pubitemid 41415923)
Micantonio T, Fagnoli M, Ricevuto E, et al.- Efficacy of treatment with tetracyclines to prevent acneiform eruption secondary to cetuximab therapy. Arch Dermatol, 2005, 141, 1173-1174. (Pubitemid 41373978)
Perez-Soler R, Delford JP.- HER1/EGFR inhibitorassociated rash : future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist, 2005, 10, 345-356. (Pubitemid 40647253)
Perez-Soler R, Saltz L.- Cutaneous adverse effects with HER1/EGFR-targeted agents : is there a silver lining ? J Clin Oncol, 2005, 23, 5235-5246. (Pubitemid 46224035)
Monti M, Motta S.- Clinical management of cutaneous toxicity of anti-EGFR agents. Int J Biol Markers, 2007, 22, S53-S61. (Pubitemid 46730023)
Lièvre A, Laurent-Puig P.- Facteurs prédictifs de réponse aux traitements anti-REGF dans le cancer colorectal. Bull Cancer, 2008, 95, 133-140. (Pubitemid 351262492)
Quatresooz P, Piérard-Franchimont C, Paquet P, et al.- Crossroads between actinic keratosis and squamous cell carcinoma, and novel pharmacological issues. Eur J Dermatol, 2008, 18, 6-10. (Pubitemid 351158165)
Lacouture ME, Desai A, Soltani K, et al.- Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor. Clin Exp Dermatol, 2006, 31, 783-785. (Pubitemid 44563396)
Hermanns JF, Quatresooz P, Piérard GE.- Taïaut! Erlotinib a vu une kératose actinique : c'est l'hallali. Dermatol Actual, 2008, 107, 24-27.
Cunningham D, Humblet Y, Siena S, et al.- Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med, 2004, 351, 337-345. (Pubitemid 38944402)
Saltz LB, Meropol NJ, Loehrer Sr. PJ, et al.- Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol, 2004, 22, 1201-1208. (Pubitemid 41079832)
Chung KY, Shia J, Kemeny NE, et al.- Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol, 2005, 23, 1803-1810. (Pubitemid 46211358)
Hebbar M, Wacrenier A, Desauw C, et al.- Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer. Anticancer Drugs, 2006, 17, 855-857. (Pubitemid 44310182)
Scartozzi M, Bearzi I, Berardi R, et al.- Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites : implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol, 2004, 22, 4772-4778. (Pubitemid 41185088)
